ABSTRACT
During our research to contribute to the elucidation of the chemical composition of the root bark of E. suaveolens, six non-nitrogenous cassane diterpenoids (1-6) were isolated and identified. Of these secondary metabolites, three have never been previously described: Cassan-13,15-dien-3-oxo-17-oic acid (2), Cassan-15-en-[7,17]-γ-lactone (3) and 6α-hydroxy-cassamic acid (5). The other are known but, never isolated from the root barks of E. suaveolens (Fabaceae): Cassan-13,15-dien-17-oic acid (1), 6α-hydroxy-cassamic acid methyl esther (4) and cassamic acid (6). Their structures were established according to the spectroscopic data (NMR 1D and 2D, HR-ESI-MS and IR), in comparison with those of literature. The originality of this study lies in the fact that three new natural molecules were isolated and identified. In addition, all the isolated compounds (1-6) were reported for the first time from the root barks of E. suaveolens.
Subject(s)
Diterpenes/isolation & purification , Fabaceae/chemistry , Carbon-13 Magnetic Resonance Spectroscopy , Diterpenes/chemistry , Plant Bark/chemistry , Plant Roots/chemistry , Proton Magnetic Resonance SpectroscopyABSTRACT
In a university hospital, time-series analysis revealed a significant relationship between antibiotic (aminoglycoside, fluoroquinolone, and cefepime) use and incidence of MexXY-OprM-overproducing Pseudomonas aeruginosa. In vitro experiments confirm that such mutants were readily selected from both PAO1 and clinical strains when grown in the presence of these antibiotics.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Outer Membrane Proteins/metabolism , Bacterial Proteins/metabolism , Drug Resistance, Multiple/genetics , Membrane Transport Proteins/metabolism , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Aminoglycosides/pharmacology , Aminoglycosides/therapeutic use , Anti-Bacterial Agents/pharmacology , Bacterial Outer Membrane Proteins/genetics , Bacterial Proteins/genetics , Cefepime , Cephalosporins/pharmacology , Cephalosporins/therapeutic use , Culture Media , Fluoroquinolones/pharmacology , Fluoroquinolones/therapeutic use , France , Hospitals, University , Humans , Incidence , Membrane Transport Proteins/genetics , Microbial Sensitivity Tests , Mutation , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Pseudomonas aeruginosa/metabolismABSTRACT
We report a case of cryptococcosis in which a serum enzyme-linked immunosorbent assay (ELISA) for Aspergillus galactomannan was positive, with no evidence of aspergillosis. Soluble antigens from 19 Cryptococcus neoformans strains and purified carbohydrates of C. neoformans capsule were thus assayed in the Aspergillus galactomannan ELISA. Antigens from all C. neoformans strains, and purified galactoxylomannan, gave a positive reaction, suggesting that C. neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan.